Mutations and amplification of ERBB2 have also been reported in ~4% of NSCLC, 2–5% of colorectal cancers, 5–20% of biliary tract tumors, and in up to 60% of salivary duct carcinomas [6,7,8,15]. This evidence concerns the gene ERBB2 and colorectal cancer.